Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab PRN versus routine dosing for wet age-related macular degeneration
2007-003853-97Phase 4Completed
- Sponsor
- Manchester University NHS Foundation Trust
- Start
- Oct 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of bevacizumab in exudative macular degeneration (2 arms), sponsored by Manchester University NHS Foundation Trust. Primary endpoints: Visual acuity at 24 months and Best-corrected visual acuity over 11 and 24 months. Started Oct 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2007-003853-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003853-97.